Background: Available anti-psychotic drugs
failed to show a positive effect on cognitive impairment, a core
symptom of schizophrenic patients. Prescribing anti-psychotics is
an essential part of patient treatment. Over the duration of
treatment anti-psychotic daily doses are often escalated to an
extreme, trying to alleviate symptoms. Sex-differences in the
course of disease, symptoms of disease, cognition and sensitivity
related to anti-psychotics are known. In contrast, the strength of
cognitive impairment under increasing anti-psychotic dosage over
time to very high anti-psychotic daily doses is not
well-established. Methods: The association of anti-psychotic dosage
amount over time with cognition in patients with schizophrenia in
due consideration of sex in a widespread patient sample of n=1029
(GRAS- cross-sectional study) will be investigated for the first
time. Approved psychometric and neurological rating scales,
detailed neuropsychological tests, structured interviews, and
evaluation of early health record concerning disease outbreak are
background for the analyses. The value “dose-increase
